From Dr. Fumi Urano today: Dec. 22, 2014 - "Why
Post# of 30025
Posted On: 12/22/2014 11:09:39 AM
From Dr. Fumi Urano today:
Dec. 22, 2014 - "Why am I interested in residual cells? There is a big difference between no residual cells and some residual cells. If we can enhance the function of residual beta cells and activate the proliferation of these cells, we may be able to increase the QOL of our patients. This is another aspect of regenerative medicine. Instead of replacing damaged tissues using stem cells, we are also trying to enhance the function of residual cells. This approach should be applicable to neuronal and retinal ganglion cells . The study is ongoing and we are getting encouraging preclinical data . Our current focus is to delay the progression using drugs, but we need to develop methods for enhancing the function and proliferation of residual beta cells and neurons."
http://wolframsyndrome.dom.wustl.edu/residual-beta-cells/
From Dr. Urfer a few months back:
Oct. 7, 2014 - "Dr. Urfer reported that a single intravitreal administration of MANF in rats with ischemia-related optic nerve damage resulted in a statistically significant protective effect of MANF on retinal function, compared to control animals, as measured by electroretinogram (ERG). Furthermore, this effect was supplemented by a strong retinal ganglion cell protective effect observed in the treatment groups. He concluded that this is a clear signal that MANF provides functional benefit in a model of retinal disorders. CRVO, central retinal artery occlusion, is an orphan indication in humans with limited treatment options. Glaucoma affects approximately 4 million individuals in the United States."
http://ir.amarantus.com/company-news/detail/1...conference
Dec. 22, 2014 - "Why am I interested in residual cells? There is a big difference between no residual cells and some residual cells. If we can enhance the function of residual beta cells and activate the proliferation of these cells, we may be able to increase the QOL of our patients. This is another aspect of regenerative medicine. Instead of replacing damaged tissues using stem cells, we are also trying to enhance the function of residual cells. This approach should be applicable to neuronal and retinal ganglion cells . The study is ongoing and we are getting encouraging preclinical data . Our current focus is to delay the progression using drugs, but we need to develop methods for enhancing the function and proliferation of residual beta cells and neurons."
http://wolframsyndrome.dom.wustl.edu/residual-beta-cells/
From Dr. Urfer a few months back:
Oct. 7, 2014 - "Dr. Urfer reported that a single intravitreal administration of MANF in rats with ischemia-related optic nerve damage resulted in a statistically significant protective effect of MANF on retinal function, compared to control animals, as measured by electroretinogram (ERG). Furthermore, this effect was supplemented by a strong retinal ganglion cell protective effect observed in the treatment groups. He concluded that this is a clear signal that MANF provides functional benefit in a model of retinal disorders. CRVO, central retinal artery occlusion, is an orphan indication in humans with limited treatment options. Glaucoma affects approximately 4 million individuals in the United States."
http://ir.amarantus.com/company-news/detail/1...conference
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼